Cingulate Inc. (CINGW)

Market Cap	23.65M
Revenue (ttm)	n/a
Net Income (ttm)	-16.38M
Shares Out	4.25M
EPS (ttm)	-7.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,679
Open	0.1190
Previous Close	0.1500
Day's Range	0.1190 - 0.1399
52-Week Range	0.0080 - 0.1800
Beta	-0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2025

About CINGW

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CINGW
• Website: https://www.cingulate.com